Trial intelligence / Profile preview

SUCCESSOR-2: Mezigdomide + Carfilzomib + Dexamethasone vs Carfilzomib + Dexamethasone in RRMM

NCT05552976Phase 3

Key facts

Status: Active, not recruiting
Start: Jan 2023
Primary completion: Sep 2026
Countries: 27
Sponsor: Bristol Myers Squibb
Modality: Molecular Glues

Drugs: mezigdomide
Conditions: multiple myeloma (MM)

Overview

Phase 3, randomised, open-label trial of mezigdomide in multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free Survival. Started Jan 2023; status: active, not recruiting.

Design

2 arms

Study design: RandomizedOpen-label

MeziKd
Mezigdomide + Carfilzomib + Dexamethasone
Kd
Carfilzomib + Dexamethasone

Who it enrols

Participants must have relapsed or refractory multiple myeloma with measurable disease, have received at least one prior line of therapy including lenalidomide and an anti-CD38 mAb, and have documented disease progression. Prior treatment with mezigdomide or carfilzomib, or recent stem cell transplants are excluded.

Endpoints

Primary

Progression-free SurvivalUp to approximately 5 years

Secondary

Recommended Mezigdomide DoseUp to 12 months
Plasma concentrations of Mezigdomide in Combination with Carfilzomib and DexamethasoneUp to 176 days
Overall SurvivalUp to approximately 5 years
Overall Response RateUp to approximately 5 years
Rate Of Very Good Partial Response Or BetterUp to approximately 5 years
Complete Response Or Better RateUp to approximately 5 years
Time To ResponseUp to approximately 5 years
Duration Of ResponseUp to approximately 5 years

Beyond the preview

Go deeper on NCT05552976.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05552976.